4Q Results Meet Expectations
Prolia, Xgeva Sales Are Amgen's Top 2011 Priority
By Tom Wall
Wednesday, January 26, 2011
Amgen Inc.'s future, in particular the prospects for recently approved drugs Prolia and Xgeva, have gotten much of the attention this week as the Thousand Oaks, Calif.-company reported fourth-quarter and full-year 2010 financial results. But CEO Kevin Sharer put things in perspective when he reminded listeners during a conference call that the future is in large measure the past: it took 15 years of work to develop the products and set the stage for Amgen's promising outlook.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.